^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CCR4 receptor antagonist

    Related drugs:
    29d
    scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions. (PubMed, J Eur Acad Dermatol Venereol)
    Our study provides novel insights into the molecular properties of residual malignant clones within MAR that appear silenced, surrounded by a putatively anti-tumor immune response.
    Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • MMP2 (Matrix metallopeptidase 2) • CCR7 (Chemokine (C-C motif) receptor 7) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • FOXP3 (Forkhead Box P3) • GZMA (Granzyme A) • RUNX3 (RUNX Family Transcription Factor 3)
    |
    Poteligeo (mogamulizumab-kpkc)
    1m
    Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab. (PubMed, Clin Immunol)
    LMR is a novel prognostic factor in r/r ATL and may provide useful information when considering mogamulizumab-based treatment.
    Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    Poteligeo (mogamulizumab-kpkc)
    1m
    Repurposing of Chemokine Antagonists for Combined Phase-Resolved Spinal Cord Injury Treatment. (PubMed, Adv Sci (Weinh))
    The effects of mogamulizumab and chemical antagonists of C-C/C-X-C chemokine receptors TAK-799, SB225002, and MK-7123 on SCI recovery in rodents are further estimated. Here blockade of CCR5 and CXCR1/2 chemokine receptors is shown beneficial for amelioration of acute SCI, whereas anti-CCR4 antibody mogamulizumab readily prevents secondary inflammation in the injured area. Summarizing, the current report claims for a novel combined time-resolved therapeutic modality in SCI treatment, which supports feasibility and motivates off-label clinical evaluation in appropriate cohorts.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2 (Interleukin 2) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • IL7 (Interleukin 7) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    Poteligeo (mogamulizumab-kpkc) • SB225002 • navarixin (MK-7123)
    2ms
    Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma (clinicaltrials.gov)
    P2, N=34, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Poteligeo (mogamulizumab-kpkc)
    3ms
    A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy (clinicaltrials.gov)
    P4, N=23, Active, not recruiting, Kyowa Kirin China Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Poteligeo (mogamulizumab-kpkc)
    3ms
    Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas. (PubMed, Lancet Haematol)
    Monoclonal antibodies or antibody-drug conjugates targeting T-cell lymphoma surface antigens have been approved, including brentuximab vedotin, for the treatment of CD30-positive nodal and cutaneous T-cell lymphoma, and mogamulizumab, for mycosis fungoides and adult T-cell leukaemia/lymphoma. Novel approaches including cell therapy and adoptive immunotherapy are currently being evaluated. In this Series paper, we discuss the limitations of the conventional treatment options and the use of these novel approaches for mature T-cell and natural killer-cell lymphomas.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)
    3ms
    Bridging therapy with valemetostat to allogeneic hematopoietic cell transplantation for adult T-cell leukemia/lymphoma. (PubMed, J Clin Exp Hematop)
    No significant adverse effects of valemetostat were observed early after transplantation, in contrast to the increased incidence of severe GVHD and non-relapse mortality reported following allo-HCT after mogamulizumab therapy. These findings suggest that valemetostat is a promising option as a bridging therapy to allo-HCT for aggressive ATL.
    Journal
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    Poteligeo (mogamulizumab-kpkc) • Ezharmia (valemetostat)
    4ms
    Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance (clinicaltrials.gov)
    P=N/A, N=15, Recruiting, Kyowa Kirin Co., Ltd.
    New trial
    |
    Poteligeo (mogamulizumab-kpkc)
    4ms
    Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma. (PubMed, Leuk Lymphoma)
    These findings suggest a potential beneficial effect of Romi-Moga therapy when administered in close sequence. Prospective studies are needed to validate these results and optimize treatment strategies.
    Journal
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    Istodax (romidepsin) • Poteligeo (mogamulizumab-kpkc)
    5ms
    FIL_MOGA: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Poteligeo (mogamulizumab-kpkc)